CCM
HAE icon

Credo Capital Management’s Haemonetics HAE Stock Holding History

Credo Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$193K Sell
4,591
-9,110
-66% -$375K 0.83% 62
2013
Q3 		$546K Buy
+13,701
New +$575K 0.94% 59

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Credo Capital Management's HAE Position: Q4 2013 in Review

Credo Capital Management reduced its Haemonetics (HAE) stake by 66% in Q4 2013, selling an estimated $375K and leaving 4,591 shares worth $193K. The position accounts for 0.83% of the portfolio, ranked #62.

Credo Capital Management first reported a position in HAE in Q3 2013 and has held it in 2 quarters since. The position peaked at $546K in Q3 2013. 195 funds tracked by Wall St. Rank hold HAE as of Q4 2013.

  • Credo Capital Management held 4,591 shares of Haemonetics worth $193K as of Q4 2013.
  • Credo Capital Management sold 9,110 Haemonetics shares in Q4 2013, an estimated $375K.
  • Haemonetics made up 0.83% of Credo Capital Management's portfolio in Q4 2013, its #62 holding.
  • Credo Capital Management first reported a position in Haemonetics in Q3 2013 and has held it in 2 quarters since.
  • Credo Capital Management's Haemonetics position peaked at $546K in Q3 2013.
  • 195 funds tracked by Wall St. Rank held Haemonetics as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.